MediWound Ltd. (MDWD)
NASDAQ: MDWDHealth Care Medicinal Chemicals and Botanical Products USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MDWD stock chart
Technical analysisKey statistics
All statistics- Market cap
- $195.56M
- EPS (TTM)
- -$2.59
- Dividend yield
- None
- 52-week range
- 11.80 – 19.70
- Day range
- 13.36 – 13.62
- Volume / Avg
- 187.84K / 125.80K
- Beta
- —
- Shares outstanding
- 14.39M
52-week range
MDWD stock today
On Nov 20, MDWD ended the session at $13.59, adding $0.05 (0.37%), versus the S&P 500's 3.70% decline. At this level, MDWD sits in the middle of its 52-week range of $11.80 to $19.70: 31.0% below the high, set on Jan 8, 2026 and 15.2% above the low. MDWD is down 26.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 20.3%.
MediWound has posted a net loss over the last twelve months (EPS of -$2.59), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About MediWound
Company profileMediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers.
- Sector
- Health Care
- Industry
- Medicinal Chemicals and Botanical Products
- CEO
- Mr. Ofer Gonen B.Sc.
- Headquarters
- Yavne
- Employees
- 121
- IPO year
- 2014
- Website
- mediwound.com
Financial highlights
Full financialsIn fiscal 2025, MediWound generated $17.0 million in revenue, down 16.1% from fiscal 2024, its first annual decline since 2023. MediWound reported a net loss of $23.9 million, compared with a loss of $30.2 million a year earlier. Gross margin was 19.2% (up from 13.0%) and operating margin -149.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $16.96M | $20.22M | $18.69M | $26.50M | $23.76M |
| Growth | -16.14% | +8.22% | -29.48% | +11.50% | +9.19% |
| Net income | $-23.88M | $-30.22M | $-6.72M | $-19.60M | $-13.55M |
| EPS (diluted) | $-2.10 | $-3.03 | $-0.75 | $-3.93 | $-3.48 |
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$29.67+118.32%
- Strong buy 1
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.65 vs $-0.66
- Surprise
- +1.52%
MDWD news
All MDWD news- MediWound (MDWD) Q3 2026 Earnings Call TranscriptNasdaqMDWD, BRK.B
- MediWound Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateGlobeNewswire
- MediWound Ltd. Enters Underwriting Agreement for $17.25 million Public OfferingNasdaq
- MediWound Announces $15 Million Bought Deal Offering of Ordinary SharesGlobeNewswire
- Madrigal (MDGL) Q3 Earnings and Revenues Beat EstimatesNasdaqMDGL, MDWD
MediWound peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CGCCanopy Growth Corporation | 0.427 | -9.97% | $191.99M | vs MDWD |
| USNAUSANA Health Sciences Inc. | 12.94 | -1.67% | $239.24M | vs MDWD |
| NAGENiagen Bioscience Inc. | 1.84 | -1.60% | $145.72M | vs MDWD |
| GLASGlass House Brands Inc. Subordinate Voting Shares | 1.18 | -2.48% | $118.11M | vs MDWD |
| ACBAurora Cannabis Inc. | 4.16 | -2.35% | $273.50M | vs MDWD |
| TLRYTilray Brands Inc. | 1.89 | -8.70% | $279.32M | vs MDWD |
| SNDLSNDL Inc. | 1.17 | -5.65% | $285.20M | vs MDWD |
| ISPRIspire Technology Inc. | 1.23 | -3.15% | $71.05M | vs MDWD |
Indexes, lists and sector
MediWound stock FAQ
What is MediWound's stock price today?
MDWD last traded at $13.59 as of Nov 20, 4:00 PM EST, up 0.37% on the day. Prices are delayed at least 15 minutes.
Does MediWound pay a dividend?
No. MediWound does not currently pay a regular cash dividend.
Who is MediWound's CEO?
Mr. Ofer Gonen B.Sc. is the chief executive officer of MediWound Ltd., which has about 121 employees.
Has MDWD ever split its stock?
Yes. The most recent MDWD stock split was a 1-for-7 split on Dec 20, 2022.
What is the MDWD 52-week high?
The 52-week high for MDWD is $19.70 and the 52-week low is $11.80. The stock is currently 31.0% below its high.